Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

Therapeutic effect of Xuezhitong capsule on microvascular angina

Xiaomei Ma¹, Dehui Yang², Weichun Shen³, Wei Liang², Qian Lin⁴

¹Traditional Chinese Medicine Department, Beijing City Fengtai District Nanyuan Hospital, Beijing; ²Changchun University of Chinese Medicine, Changchun City; ³Beijing Huashi Kangyuan Pharmaceutical Technology Co. Ltd; ⁴Department of Cardiology, Dongzhimen Hospital Beijing University of Chinese Medicine, Beijing, China.

For correspondence:- Qian Lin Email: niduizhan017358749@163.com

Accepted: 20 August 2021 Published: 30 September 2021

Citation: Ma X, Yang D, Shen W, Liang W, Lin Q. Therapeutic effect of Xuezhitong capsule on microvascular angina. Trop J Pharm Res 2021; 20(9):1991-1997 doi: 10.4314/tjpr.v20i9.28

© 2021 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To determine the therapeutic effect of Xuezhitong capsule in patients with microvascular angina (MVA), and its impact on vascular endothelial function.

Methods: In total, 172 MVA patients treated in Beijing City Fengtai District Nanyuan Hospital from September 2017 to September 2019 were selected and randomized into control group which received conventional treatment, and treatment group which received Xuezhitong capsules plus. There were 86 patients in each group. Therapeutic effect, levels of inflammatory factors, i.e., high-sensitivity C-reactive protein (hs-CRP), interleukin-(IL-6), tumor necrosis factor-α (TNF-α), and vascular endothelial factors such as nitric oxide (NO), thromboxane B2 (TXB2) and endothelin (ET), were determined.

Results: Markedly higher total treatment effectiveness was observed in the treatment group than in the control group (89.53 % vs. 72.94 %; p < 0.05). In both groups, treatment reduced the levels of hs-CRP, IL-6, TNF-α, TXB2 and ET, but elevated NO, with better results for treatment group than the control group (p < 0.05). Better optimizations of total cholesterol (TC), triglycerides (TGs), low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein (HDL) were observed in the treatment group, relative to the control group (p < 0.05). Patients in the treatment group experienced fewer (8.14 %) adverse reactions than those in control group (21.18 %, p < 0.05).

Conclusion: Xuezhitong capsule, when combined with conventional treatment, exerts high therapeutic effectiveness and safety in MVA patients by inhibiting inflammatory reactions, optimizing endothelial function, reducing blood lipid levels, and decreasing the incidence of cardiovascular adverse events. Thus, the combination therapy is a potentially superior therapeutic strategy to the conventional approach for the management of MVA patients.

Keywords: Xuezhitong capsule, MVA, Vascular endothelial function, Inflammatory factors, Blood lipids